XT
CVKD icon

XTX Topco’s Cadrenal Therapeutics CVKD Stock Holding History

XTX Topco’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,316
Closed -$12K – 1981
2024
Q1 		$12K Buy
+1,316
New +$16.7K ﹤0.01% 1662

Other funds holding CVKD

APP
Avantax Planning Partners Dubuque, Iowa $3.64B AUM 14.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BFO
Biltmore Family Office Charlotte, North Carolina $716M AUM 21.09% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

XTX Topco's CVKD Position: Q2 2024 in Review

XTX Topco sold out of Cadrenal Therapeutics (CVKD) in Q2 2024, closing a stake of 1,316 shares — an estimated $12K sold.

XTX Topco first reported a position in CVKD in Q1 2024 and held it in 1 quarter. The position peaked at $12K in Q1 2024. 9 funds tracked by Wall St. Rank hold CVKD as of Q2 2024.

  • XTX Topco reported no remaining Cadrenal Therapeutics position as of Q2 2024 after selling out during the quarter.
  • XTX Topco sold 1,316 Cadrenal Therapeutics shares in Q2 2024, an estimated $12K.
  • XTX Topco first reported a position in Cadrenal Therapeutics in Q1 2024 and held it in 1 quarter.
  • XTX Topco's Cadrenal Therapeutics position peaked at $12K in Q1 2024.
  • 9 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q2 2024.

Based on XTX Topco's 13F filing for Q2 2024, filed 12 Aug 2024.